Kymera Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($0.95) Per Share (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a research note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($0.95) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.86) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics’ Q4 2024 earnings at ($1.00) EPS, FY2024 earnings at ($3.25) EPS, FY2025 earnings at ($3.77) EPS and FY2026 earnings at ($3.92) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.10. The firm had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The business’s revenue for the quarter was up 55.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.67) EPS.

Other equities analysts also recently issued reports about the company. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 target price for the company in a research report on Monday, August 26th. B. Riley upped their target price on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 9th. Leerink Partners reiterated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Monday. HC Wainwright restated a “buy” rating and issued a $46.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 17th. Finally, Wells Fargo & Company increased their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $48.67.

Kymera Therapeutics Trading Down 0.1 %

Shares of NASDAQ KYMR opened at $44.72 on Wednesday. The stock has a market capitalization of $2.74 billion, a PE ratio of -17.82 and a beta of 2.22. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $50.19. The stock has a fifty day simple moving average of $43.93 and a 200-day simple moving average of $38.89.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $78,000. Comerica Bank boosted its stake in Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares during the period. Public Employees Retirement Association of Colorado purchased a new position in Kymera Therapeutics during the 2nd quarter worth $139,000. Ameritas Investment Partners Inc. increased its stake in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after purchasing an additional 295 shares during the period. Finally, XTX Topco Ltd acquired a new position in Kymera Therapeutics in the second quarter valued at $201,000.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 453,960 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total value of $17,345,811.60. Following the completion of the sale, the director now directly owns 723,246 shares of the company’s stock, valued at $27,635,229.66. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 482,105 shares of company stock valued at $18,651,584. Corporate insiders own 15.82% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.